trending Market Intelligence /marketintelligence/en/news-insights/trending/EYOomvBnGsq6DYG4_ujIng2 content esgSubNav
In This List

Marksans secures US approval to market generic benign prostatic hyperplasia drug

Blog

Insight Weekly: US inflation soars; real estate faces slowdown; megadeals drive tech M&A

Blog

Commercial Banking: June 22nd Edition

Blog

Understanding Loss Given Default A Review of Three Approaches

Blog

Insight Weekly: Path to net-zero; US manufacturing momentum; China's lithium M&A frenzy


Marksans secures US approval to market generic benign prostatic hyperplasia drug

Marksans Pharma Ltd. secured U.S. FDA approval to market a generic version of GlaxoSmithKline PLC's Avodart for the treatment of benign prostatic hyperplasia, or BPH.

BPH is an age-associated prostate gland enlargement that can cause urination difficulty. The Indian pharmaceutical said it will launch dutasteride soft gelatin capsules in dosages of 0.5 milligrams immediately.

Elsewhere, the company noted that the U.S. FDA recorded four violations during an inspection of its manufacturing facility in Goa, India.

Marksans said it had already started addressing the issues.